Skip to main content
Journal cover image

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

Publication ,  Journal Article
Lambert, JS; Keefer, M; Mulligan, MJ; Schwartz, D; Mestecky, J; Weinhold, K; Smith, C; Hsieh, R; Moldoveanu, Z; Fast, P; Forrest, B; Koff, W
Published in: Vaccine
April 30, 2001

Thirty-three HIV-seronegative adults were recruited into a Phase I safety and immunogenicity HIV-1 vaccine trial. The immunogens were as follows: a synthetic, monovalent, octameric HIV-1 MN V3 peptide in aluminum hydroxide (alum) adjuvant administered by intramuscular delivery; and a similar product encapsulated in biodegradable micro-spheres composed of co-polymers of lactic and glycolic acids, administered by the oral route. These were administered in three sequential oral doses, followed by a parenteral boost. No serious adverse experiences were observed. Oral administration of this vaccine, alone or in combination with parenteral boosting, resulted in no significant humoral, cellular, or mucosal immune responses.

Duke Scholars

Published In

Vaccine

DOI

ISSN

0264-410X

Publication Date

April 30, 2001

Volume

19

Issue

23-24

Start / End Page

3033 / 3042

Location

Netherlands

Related Subject Headings

  • Virology
  • T-Lymphocytes, Cytotoxic
  • Safety
  • Peptide Fragments
  • Middle Aged
  • Microspheres
  • Male
  • Lymphocyte Activation
  • In Vitro Techniques
  • Immunization, Secondary
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lambert, J. S., Keefer, M., Mulligan, M. J., Schwartz, D., Mestecky, J., Weinhold, K., … Koff, W. (2001). A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine, 19(23–24), 3033–3042. https://doi.org/10.1016/s0264-410x(01)00051-2
Lambert, J. S., M. Keefer, M. J. Mulligan, D. Schwartz, J. Mestecky, K. Weinhold, C. Smith, et al. “A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.Vaccine 19, no. 23–24 (April 30, 2001): 3033–42. https://doi.org/10.1016/s0264-410x(01)00051-2.
Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine. 2001 Apr 30;19(23–24):3033–42.
Lambert, J. S., et al. “A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.Vaccine, vol. 19, no. 23–24, Apr. 2001, pp. 3033–42. Pubmed, doi:10.1016/s0264-410x(01)00051-2.
Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine. 2001 Apr 30;19(23–24):3033–3042.
Journal cover image

Published In

Vaccine

DOI

ISSN

0264-410X

Publication Date

April 30, 2001

Volume

19

Issue

23-24

Start / End Page

3033 / 3042

Location

Netherlands

Related Subject Headings

  • Virology
  • T-Lymphocytes, Cytotoxic
  • Safety
  • Peptide Fragments
  • Middle Aged
  • Microspheres
  • Male
  • Lymphocyte Activation
  • In Vitro Techniques
  • Immunization, Secondary